Updates in Management of SARS-CoV-2 Infection
Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) has spread worldwide from the beginning of 2020. The infection is mostly asymptomatic but some patients may develop COVID‑19 (coronavirus disease 2019) with a severe or critical course leading to pneumonia, acute respiratory distress syndr...
Saved in:
Sonstige: | |
---|---|
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (198 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993562969404498 |
---|---|
ctrlnum |
(CKB)5670000000391571 (oapen)https://directory.doabooks.org/handle/20.500.12854/93224 (EXLCZ)995670000000391571 |
collection |
bib_alma |
record_format |
marc |
spelling |
Flisiak, Robert edt Updates in Management of SARS-CoV-2 Infection MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (198 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) has spread worldwide from the beginning of 2020. The infection is mostly asymptomatic but some patients may develop COVID‑19 (coronavirus disease 2019) with a severe or critical course leading to pneumonia, acute respiratory distress syndrome, and multiorgan failure. Apart from the virus‑related damage of the lungs, pathomechanism of the disease seems to be linked to thromboembolism and inflammation accompanied by overproduction of proinflammatory cytokines, termed a cytokine storm, responsible for multiorgan damage and death. Since the development of a new therapeutic molecule, dedicated strictly to a particular virus is time‑consuming, physicians and scientists have started to test and repurpose old medications. Unfortunately, after one year of pandemics, there is still a lack of optimal therapy and no clear indicators of recovery. A major issue is also insufficient knowledge on predictors of the severe or deadly course of the disease, which could also help to switch from one therapeutic option to another. Due to many gaps still existing in the management of COVID-19, there is a need for the accumulation of new data particularly from real-world experience, which could be applicable to practice guidelines. The objective of this special issue of the Journal of Clinical Medicine is to provide an update on the mangement for the diagnostic workup and pharmacotherapy of SARS‑CoV‑2 infection. English Medicine bicssc COVID-19 SARS-CoV-2 interleukin-6 tocilizumab therapy coronavirus disease 2019 cytokines severity prognosis mortality kidney failure rapid diagnostic test antigen detection Cytomegalovirus co-infections critical care liver markers inflammation morbidity personalized medicine liver functional tests COVID-19 pneumonia meta-analysis trial sequential analysis children clinical presentation coronavirus disease 2019 (COVID-19) epidemiology severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clinical outcome symptomatology pandemic angiotensin 1 receptor (AT1R) AT1R concentration angiotensin II symptoms' severity diagnosis artificial intelligence medical imaging systematic umbrella review methodological credibility PCR test COVID-19 diagnosis Charlson Comorbidities Index cluster analysis longitudinal cluster individualized management 3-0365-5389-4 Flisiak, Robert oth |
language |
English |
format |
eBook |
author2 |
Flisiak, Robert |
author_facet |
Flisiak, Robert |
author2_variant |
r f rf |
author2_role |
Sonstige |
title |
Updates in Management of SARS-CoV-2 Infection |
spellingShingle |
Updates in Management of SARS-CoV-2 Infection |
title_full |
Updates in Management of SARS-CoV-2 Infection |
title_fullStr |
Updates in Management of SARS-CoV-2 Infection |
title_full_unstemmed |
Updates in Management of SARS-CoV-2 Infection |
title_auth |
Updates in Management of SARS-CoV-2 Infection |
title_new |
Updates in Management of SARS-CoV-2 Infection |
title_sort |
updates in management of sars-cov-2 infection |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2022 |
physical |
1 electronic resource (198 p.) |
isbn |
3-0365-5390-8 3-0365-5389-4 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT flisiakrobert updatesinmanagementofsarscov2infection |
status_str |
n |
ids_txt_mv |
(CKB)5670000000391571 (oapen)https://directory.doabooks.org/handle/20.500.12854/93224 (EXLCZ)995670000000391571 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Updates in Management of SARS-CoV-2 Infection |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796649014622420993 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03993nam-a2200853z--4500</leader><controlfield tag="001">993562969404498</controlfield><controlfield tag="005">20231214132956.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202210s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-0365-5390-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5670000000391571</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/93224</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995670000000391571</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Flisiak, Robert</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Updates in Management of SARS-CoV-2 Infection</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (198 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) has spread worldwide from the beginning of 2020. The infection is mostly asymptomatic but some patients may develop COVID‑19 (coronavirus disease 2019) with a severe or critical course leading to pneumonia, acute respiratory distress syndrome, and multiorgan failure. Apart from the virus‑related damage of the lungs, pathomechanism of the disease seems to be linked to thromboembolism and inflammation accompanied by overproduction of proinflammatory cytokines, termed a cytokine storm, responsible for multiorgan damage and death. Since the development of a new therapeutic molecule, dedicated strictly to a particular virus is time‑consuming, physicians and scientists have started to test and repurpose old medications. Unfortunately, after one year of pandemics, there is still a lack of optimal therapy and no clear indicators of recovery. A major issue is also insufficient knowledge on predictors of the severe or deadly course of the disease, which could also help to switch from one therapeutic option to another. Due to many gaps still existing in the management of COVID-19, there is a need for the accumulation of new data particularly from real-world experience, which could be applicable to practice guidelines. The objective of this special issue of the Journal of Clinical Medicine is to provide an update on the mangement for the diagnostic workup and pharmacotherapy of SARS‑CoV‑2 infection.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">COVID-19</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SARS-CoV-2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">interleukin-6</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tocilizumab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">coronavirus disease 2019</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytokines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">severity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mortality</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">kidney failure</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">rapid diagnostic test</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antigen detection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cytomegalovirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">co-infections</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">critical care</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liver markers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">morbidity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">personalized medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liver functional tests</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">COVID-19 pneumonia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">trial sequential analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">children</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical presentation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">coronavirus disease 2019 (COVID-19)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epidemiology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical outcome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">symptomatology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pandemic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">angiotensin 1 receptor (AT1R)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AT1R concentration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">angiotensin II</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">symptoms' severity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">diagnosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">artificial intelligence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">medical imaging</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">systematic umbrella review</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">methodological credibility</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PCR test</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">COVID-19 diagnosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Charlson Comorbidities Index</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cluster analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">longitudinal cluster</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">individualized management</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-5389-4</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Flisiak, Robert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:38:49 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-11-05 21:33:14 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5340570430004498&Force_direct=true</subfield><subfield code="Z">5340570430004498</subfield><subfield code="b">Available</subfield><subfield code="8">5340570430004498</subfield></datafield></record></collection> |